Billionaire Family Offices Invest in Biotech and Health Care Startups
In August, billionaire family offices made 52 direct investments into private companies, with biotechnology startups accounting for about 20% of the transactions. Notable deals included LifeMine Therapeutics securing $188 million from Bezos Expeditions and Gates Frontier, while Duquesne Family Office led a $90 million Series C round in Epicrispr Biotechnologies. The resurgence is attributed to artificial intelligence's role in drug discovery and diagnostics. The venture capital landscape for biopharma has seen a rebound this year as investors increasingly focus on companies with drugs already in clinical testing rather than early-stage startups. U.S. and European biotech firms raised $12.6 billion in the first half of 2026, marking a five-year high according to Silicon Valley Bank data. Family offices are showing strong confidence in health care innovation, particularly where AI is being used for drug development and genomic analysis.
Topics: artificial intelligence biotechnology family offices investments